PluriStem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PluriStem Therapeutics Inc. on February 5, 2014, reporting events that occurred on February 4, 2014. The company is incorporated in Nevada and maintains its principal executive offices in Haifa, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of two new senior officers effective February 4, 2014:
- Yaky Yanay was appointed President and Chief Operating Officer. He previously served as the company's CFO and Secretary since 2006 and Executive Vice President since 2013.
- Boaz Gur-Lavie was appointed Chief Financial Officer and Secretary. He joined the company as Vice President of Finance on January 1, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is limited to the disclosure of officer appointments and their professional backgrounds.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (February 4, 2014).
- Verify the professional backgrounds of the new President/COO (Yaky Yanay) and CFO (Boaz Gur-Lavie) as disclosed.
- Note that this filing does not contain financial results; investors should refer to the most recent 10-K or 10-Q for financial data.